Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Jul 20th, 2009 | By buddy1 | Category: Health & Wellness News, Pharmaceutical HeadlinesHeptax, the Company’s lead compound, reduces cholesterol, triglycerides, blood pressure, liver enzymes, and fasting blood glucose levels in animal models of metabolic syndrome and liver disease. It also raised levels of HDL, the “good cholesterol.”
